Great news and a quick cure for COVID-19..no joke

[Wallfire]

News from Finland

A breakthrough in a Turku-based pharmaceutical company can bring relief to its corona pandemic


 
Anna Egutkina
 
1 hour ago



[/url]


© Edited by MTV
A Finnish drug project is believed to help with coronavirus lung disease by restoring capillary integrity.

Yle uutiso i today the Turku-based drug company Faron Pharmaceuticals developed Traumakine-drug, that arouses intense interest, especially now, because it is believed to help koronaviruspandemiaan.

Markku Jalkanen, CEO of Faron Pharmaceuticals Oy, tells MTV News that it is not possible to talk about the drug yet, but Traumakine is currently the name of the project.

“We don't have a drug yet, but a clinical study that regulates the expression of the CD73 molecule, which is involved in maintaining lung capillaries. What always works is the human peptide hormone interferon beta, which is also induced by all viral infections in response to limiting viral infection, Jalkanen says.
© Edku Markku Jalkanen, Managing Director of MTV Faron Pharmaceuticals Oy, says that Traumaquinea has been developed for over 10 years. Photo: Faron Pharmaceuticals Oy
According to Jalkanen, the regulation of the CD73 molecule is particularly important in the lungs, where gas exchange takes place in the capillaries. If gases leak into the lungs, severe pulmonary insufficiency occurs. Coronary patients die of this condition and are commonly referred to as acute respiratory distress syndrome (ARDS). 





The first coronavirus death did not surprise authorities - in a direct interview with THL's CEO
MTV News Live
7 min

Video Player from: MTV ( [url=https://www.mtv.fi/yritys/tietosuoja]Privacy Policy )

- Traumaquin is intended to prevent or limit the development or progression of ARDS by restoring capillary integrity.



Further research is needed

Traumatic development work has been ongoing for more than a decade and has included a number of clinical trials around the world.

The marketing of the finished medicinal product to the Finnish market, ie the marketing authorization, is subject to regulatory approval through clinical trials and is not available until further investigation. Jalkanen estimates that it will take 2-3 years to obtain a marketing authorization. In theory, Traumakine can also be introduced on an accelerated schedule, but it requires the permission of the Finnish Medicines Agency, Fimea.

According to Jalkanen, the risks associated with the substance are lower than normal, because our own body produces the same substance anyway, but not necessarily enough. Previous drug trials have realized the high risk associated with duplicate use of corticosteroids, which in turn prevented the effect of Trauma.

- This error will be corrected in the following studies, which do not allow their duplication, Jalkanen adds.

link